Israel
hyperlipidemia drugs market is expected to grow at an impressive rate during
the forecast period, 2024-2028. The major factors
include increasing prevalence of hyperlipidemia due
to rising cardiovascular diseases over the past few years. Furthermore,
the rising geriatric population with high levels of cholesterol and
cardiovascular diseases, is also expected to drive the growth of Israel hyperlipidemia
drugs market. According
to the Israel Medical Association Journal (IMAJ), hyperlipidemia is a major
risk factor for coronary heart disease. Therefore, reducing low density
lipoprotein-cholesterol can significantly reduce the risk of heart stroke.
Hyperlipidemia, or high cholesterol, refers to a medical
ailment characterized by prominent levels of fats in the bloodstream. It is the abnormal rise of lipids
and/or lipoprotein levels that can lead to stroke, peripheral vascular disease,
atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. It is usually caused by genetic
factors, unhealthy lifestyles, and inadequate diet. Some of the commonly used
hyperlipidemia drugs include statins, proprotein convertase subtilisin/kexin type
9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or
fibrates, and combination and miscellaneous antihyperlipidemic agents. These
drugs reduce cholesterol production levels in the liver while further removing
it from the bloodstream. Thereby, propels the growth of Israel hyperlipidemia
drugs market.
Development of New and Improved Drugs
Israel hyperlipidemia drugs market has benefited from
the development of new and improved drugs to manage cholesterol levels. For
example, PCSK9 inhibitors are a newer class of drugs that have been effective
in reducing LDL cholesterol levels. As more effective drugs are being developed
and approved, the Israel hyperlipidemia drugs market is expected to continue to
grow. The development of improved drugs
for hyperlipidemia seems to be a critical area of research, as current
therapies, such as statins, may not be effective for all patients and can have
side effects. For instance, proprotein convertase subtilisin/kexin type 9
(PCSK9) inhibitors are a new class of drugs that work by blocking the PCSK9 protein,
which participates in the metabolism of LDL cholesterol. These drugs have been
shown to significantly reduce LDL cholesterol levels in patients with
hyperlipidemia, including those with familial hypercholesterolemia, and are well-tolerated.
Additionally, bempedoic acid is a new drug that works by inhibiting ATP citrate
lyase, an enzyme involved in the synthesis of cholesterol in the liver.
Clinical trials have shown that bempedoic acid can significantly reduce LDL
cholesterol levels in patients with hyperlipidemia, including those who are
statin-intolerant or have other risk factors.
Moreover, therapies like RNA based therapies, gene therapy, and
combination therapy are cooperating to the growth of Israel hyperlipidemic
drugs market. For instance, RNA-based
therapies, including antisense oligonucleotides and small interfering RNAs
(siRNAs), are being developed to target specific genes involved in cholesterol
metabolism, such as PCSK9. These therapies have shown promising results in
early-stage clinical trials and may provide a more targeted approach to
hyperlipidemia management. These factors can bolster to the growth of the
Israel hyperlipidemic drugs market.
Download Free Sample Report
Recent Developments
- In December 2021, Novartis AG announced the U.S. Food and
Drug Administration (FDA) approval of Leqvio (inclisiran). It lowers
low-density lipoprotein cholesterol with two doses annually, following a first
dose and one after three months, and is the first and only small interfering
RNA (siRNA) therapy to do so. Leqvio increases the liver's natural capacity to
suppress the production of a protein that contributes to elevated blood
cholesterol levels, which lowers LDL-C levels in the bloodstream.
- Many clinical trials have been conducted by the market
players on the study of statin treatment for dyslipidemia.
- For instance, in November 2021, Pfizer Ltd announced topline
results from the Phase 2b study of vupanorsen (PF-07285557), an experimental
antisense treatment being researched for indications in cardiovascular (CV)
risk reduction and severe hypertriglyceridemia (SHTG), had topline data from
the Phase 2b study released by Pfizer. According to the study, vupanorsen
significantly reduced non-HDL-C, triglycerides, and other lipoproteins linked
to cardiovascular disease.
- Additionally, in September 2022, the University of
Pennsylvania started a clinical trial to evaluate the efficiency of statins
based on non-visit and visit-based interventions for their optimized referral
to patients affected by hyperlipidemia. Such studies which focus on the
utilization of statins for the lipid disorders are expected to add to the
growth of the market segment over the forecast period.
Increasing
Prevalence of Hyperlipidemia
The
rising prevalence of hyperlipidemia across the globe is estimated to enhance
the market's growth. Along with this, the rising awareness among population
about the risk of cardiovascular diseases due to persistent hyperlipidemia will
propel the growth rate of hyperlipidemia drugs market. According to Current Status of
Cardiovascular Medicine in Israel, heart disease is the second cause of
mortality (after cancer) and in recent years accounted for 15% of the total
number of deaths. Additionally, Israel has one of the lowest age-standardized mortality rates
attributable to cardiovascular causes (64 per 100 000 population). Furthermore, cardiac diseases affect 10.2% of Israeli men and 7.1% of
women, with a prevalence of coronary artery disease of 7.5% and 4.1%,
respectively. Cardiac disorders increase with age, 42% of men and 31% of
women aged ≥75 years have a cardiac illness. Therefore, augmenting national
measures to prevent heart diseases is one of the biggest challenges and unmet
needs of the Israeli healthcare system which further adds on to the growth of
Israel hyperlipidemia drugs market.
Additionally,
there are several factors that contribute to the increasing prevalence of
hyperlipidemia in Israel. One of the main factors is a shift towards a western-style
diet, which is high in saturated and trans fats and low in fruits, vegetables,
and whole grains. This diet has been associated with an increased risk of
hyperlipidemia and other chronic health conditions. Another factor is the aging
population in Israel. As the population ages, the prevalence of hyperlipidemia
increases, as older adults are more likely to have other chronic health
conditions and lifestyle factors that contribute to hyperlipidemia. Obesity is
also a significant risk factor for hyperlipidemia, and rates of obesity in
Israel have been increasing in recent years. According to a report by the
Israel’s Ministry of Health, the prevalence of obesity among Israeli adults
increased from 14% in 2003 to 26% in 2015 and it has been increased by 62
percent of men and 55% of women. Additionally, there is a genetic
predisposition to hyperlipidemia in certain populations, including those of
Middle Eastern and North African descent. As Israel has a diverse population,
including a considerable proportion of individuals with Middle Eastern and
North African ancestry, this may contribute to the higher prevalence of
hyperlipidemia in the country.
Furthermore,
the growing awareness and support provided by the Israel government includes
healthcare facilities and infrastructure. In Israel, approximately 25,000
hospitalizations occur because of myocardial infarction each year; 43,000
patients have coronary angiograms annually, and 23,000 patients undergo
percutaneous coronary interventions, mostly in the same setting as diagnostic
procedures, but approximately 50% occur during hospitalization because of acute
coronary syndrome (ACS). These factors are expected to participate in the
growth of Israel hyperlipidemia drugs market.
Market Segmentation
Israel
hyperlipidemia drugs market is segmented by drug
class, distribution channel, and region. By drug
class, the market is segmented into statins, bile acid sequestrants,
cholesterol absorption inhibitors, pcsk9 inhibitors, combination, and others.
Based on distribution channel, the market can be segmented
into hospital pharmacy, retail pharmacy, and online pharmacy.
Market Players
Pfizer Pharmaceuticals Israel
Ltd, MERCK SERONO LTD., AstraZeneca Israel Inc, Novartis Pharma Israel Ltd, Sanofi-Aventis
Israel Ltd, GlaxoSmithKline Israel Ltd., Israel B. Abbott., Takeda Israel Inc.,
Teva Israel Ltd., and Servier Israel Inc. are some of the leading companies
operating in the Israel
hyperlipidemia drugs market.
|
Attribute
|
Details
|
|
Base Year
|
2022
|
|
Historic Data
|
2018 – 2022
|
|
Estimated Year
|
2023
|
|
Forecast Period
|
2024 – 2028
|
|
Quantitative Units
|
Revenue in USD Million, Volume Units, and
CAGR for 2018-2022 and 2023-2028
|
|
Report coverage
|
Revenue forecast, Volume forecast company share, competitive
landscape, growth factors, and trends
|
|
Segments covered
|
Drug Class
Type
Region
Company
|
|
Regional scope
|
The Mediterranean Coastal Plain, The Central Hills, The Jordan
Rift Valley, and The Negev Desert
|
|
Key companies profiled
|
Pfizer Pharmaceuticals Israel Ltd, MERCK
SERONO LTD., AstraZeneca Israel Inc, Novartis Pharma Israel Ltd,
Sanofi-Aventis Israel Ltd, GlaxoSmithKline Israel Ltd., Israel B. Abbott.,
Takeda Israel Inc., Teva Israel Ltd., and Servier Israel Inc.
|
|
Customization scope
|
10% free report customization with purchase. Addition or
alteration to country, regional & segment scope.
|
|
Pricing and purchase options
|
Avail customized purchase options to meet
your exact research needs. Explore purchase options
|
|
Delivery Format
|
PDF and Excel through Email
(We can also provide the editable version of the report in PPT/Word format on
special request)
|
Report Scope:
In this report, Israel hyperlipidemia
drugs market has been segmented into following categories, in addition to the
industry trends which have also been detailed below:
Israel Hyperlipidemia Drugs Market, By Drug Class
- Statins
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- PCSK9 Inhibitors
- Combination
- Others
Israel Hyperlipidemia Drugs Market, By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Israel Hyperlipidemia Drugs Market, By Region:
- The Mediterranean Coastal Plain
- The Central Hills
- The Jordan Rift Valley
- The Negev Desert
Competitive Landscape
Company Profiles: Detailed analysis of the
major companies present in Israel hyperlipidemia drugs market.
Available Customizations:
With the given market data, TechSci
Research offers customizations according to a company’s specific needs. The
following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Israel Hyperlipidemia Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]